Maturity-Onset Diabetes of the Young
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
Identifying Maturity-onset Diabetes of the Young in Emirati Patients
Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE
Genetic Causes of Gestational Diabetes in the Emirati Population
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)